DVX INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 996 JPY | -0.50% |
|
-0.30% | -6.39% |
| Sales 2022 | 45.5B 287M 393M | Sales 2023 | 47.48B 300M 410M | Capitalization | 9.84B 62.13M 84.93M |
|---|---|---|---|---|---|
| Net income 2022 | 863M 5.45M 7.45M | Net income 2023 | 936M 5.91M 8.08M | EV / Sales 2022 | 0.05 x |
| Net cash position 2022 | 7.85B 49.53M 67.7M | Net cash position 2023 | 8.6B 54.32M 74.25M | EV / Sales 2023 | 0.03 x |
| P/E ratio 2022 |
12.4
x | P/E ratio 2023 |
11.2
x | Employees | 319 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 34.63% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.50% |
| Managers | Title | Age | Since |
|---|---|---|---|
Satoshi Miyamoto
DIF | Director of Research - Fxd Inc | 64 | 13-07-31 |
| President | 59 | 91-07-31 | |
Kazuyuki Nakano
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Masayuki Nabeya
BRD | Director/Board Member | 66 | 86-09-30 |
Sachiko Toda
BRD | Director/Board Member | 68 | 86-03-31 |
Naohiro Hirano
ADM | Chief Administrative Officer | 57 | 10-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 32 M€ | +29.67% | ||
| 0.00% | 18 M€ | +16.15% | - | |
| 0.00% | 144,586 M€ | +14.49% | ||
| 0.00% | 66,066 M€ | +14.68% | - | |
| 0.00% | 20,721 M€ | +13.52% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 996 | -0.50% | 56,600 |
| 24-04-25 | 1,001 | +0.10% | 7,500 |
| 24-04-24 | 1,000 | 0.00% | 8,500 |
| 24-04-23 | 1,000 | +0.30% | 5,400 |
| 24-04-22 | 997 | -0.20% | 2,500 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am
More quotes
DVx Inc. is a Japan-based company mainly engaged in the sale of medical equipment for circulatory system diseases. The Company operates in two business segments. The Arrhythmia segment mainly sells cardiac pacemakers, implantable cardioverter-defibrillators (ICDs), electrode catheters and ablation catheters. The Ischemia segment is engaged in the import and sale of automated contrast medium injectors under the name ACIST, excimer laser angioplasty systems, as well as sale of coronary artery stent products as agency business. The others business is engaged in the sale of neurosurgical products, general surgery related products, gastrointestinal related products, radiation protection supplies, among others.
Calendar
2024-05-14
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -6.39% | 62.02M | |
| -3.41% | 9.4B | |
| -3.90% | 1.39B | |
| -7.38% | 1.18B | |
| -18.42% | 856M | |
| +0.48% | 470M | |
| +3.62% | 437M | |
| -49.68% | 360M | |
| -24.72% | 333M | |
| -2.42% | 212M |
- Stock Market
- Equities
- 3079 Stock
